Evaluation of serum and pleural levels tumor M2-pyruvate kinase in lung cancer patients with pleural effusion

Tiantian Zhang
Nanjing Medical University

Wei Liu
Nanjing Medical University

Li Li
Nanjing Medical University

Zou Jue
Nanjing Medical University

chunhua xu (✉ xuch2188@163.com)
Nanjing Medical University

Research Article

**Keywords:** Pleural effusion, Tumor M2-pyruvate kinase, Carcinoembryonic antigen, Lung cancer, Benign/malignant, Diagnosis

**Posted Date:** March 24th, 2022

**DOI:** https://doi.org/10.21203/rs.3.rs-1443687/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Objective: To evaluate the diagnostic value of tumor M2-pyruvate kinase (TuM2-PK) and carcinoembryonic antigen (CEA) levels in both pleural effusion and serum in the differential diagnosis of benign and malignant pleural effusion.

Methods: This prospective study was conducted among 80 patients with pleural effusion caused by benign disease (BPE group) and 125 patients with malignant pleural effusion associated with lung cancer (MPE group). The levels of TuM2-PK and CEA were measured by using sandwich enzyme-linked immunosorbent assay and electrochemiluminescence. The receiver-operating characteristic curve (ROC) analysis was used to confirm the optimal critical value to evaluate the diagnostic efficiency of TuM2-PK and CEA.

Results: The TuM2-PK and CEA levels in pleural effusion and serum, and their ratio (P/S) were higher in MPE group than that in BPE group (P<0.05). In pleural effusion and serum, the diagnostic efficiency of combined TuM2-PK and CEA for MPE was superior to either single detection.

Conclusions: The combined detection of TuM2-PK and CEA has a high sensitivity for diagnosis of MPE and provides important information for rapid and accurate diagnosis of patients.

Background

Pleural effusion is a common clinical disease, even the first symptom. There are many causes of pleural effusion, mainly tuberculosis and tumor in China [1]. Lung cancer is the most common malignant pleural effusion, about 20% of which is the first symptom, and 30% ~ 40% occurs in the course of the disease [2–4]. Accurate judgment of benign pleural effusion (BPE) and malignant pleural effusion (MPE) is very important for the treatment of diseases, especially for patients with MPE. The delay of diagnosis means the reduction of quality of life and the shortening of survival time. Traditional pleural effusion examination has limited differential diagnosis between benign and malignant. Exfoliative cytology and pleural biopsy are the gold standard for the diagnosis of MPE, but the sensitivity is only 35% ~ 60%. Thoracoscopy and thoracotomy biopsy can improve the diagnostic yield, but often increase the incidence of complications and prolong the hospital stay [5, 6]. Therefore, the search for non-invasive identification methods with high sensitivity and specificity has attracted much clinical attention.

Pyruvate-kinase (PK) is a key enzyme in the glycolytic process that controls the generation of nucleotide triphosphate. The enzyme has different tissue-specific isoforms and is a homologous tetramer in their activate state. In tumor cells, the isoenzyme M2-PK is converted to dimer form, overexpressed in multistep carcinogenesis and present in blood and other body fluids, possibly released from tumor cells by necrosis and cell renewal [7–9]. To our knowledge there are few studies so far that have investigated the presence of TuM2-PK in pleural effusion. CEA is secreted by a variety of malignant tumors. When tumors invade the pleura, a large amount of secreted CEA is released into pleural effusion, resulting in that CEA in MPE is much higher than that in serum [10–14].
In this study, we analyzed the value of TuM2-PK and CEA in the differential diagnosis of BPE and MPE by detecting the levels of pleural effusion and serum TuM2-PK and CEA.

**Methods**

**Patients**

The study included 205 patients with pleural effusion recruited from Nanjing Brain Hospital. All pleural effusion had a definite etiology, which was recorded by biochemical examination, cytology, pleural biopsy, percutaneous biopsy, endoscopy and clinical follow-up. In MPE group, 80 males and 45 females were aged \( (58.5 \pm 11.8) \) years. There were 80 patients with lung adenocarcinoma (ADC), 25 patients with squamous cell carcinoma (SCC) and 20 patients with small cell lung cancer (SCLC). In BPE group, 50 males and 30 females were aged \( (59.2 \pm 10.6) \) years. There were 50 patients with tuberculosis and 30 patients with pneumonia. There was no significant difference in sex and age between the two groups (\( P > 0.05 \)).

**Diagnostic criteria for pleural effusion**

According to Light's criteria, all pleural effusions were diagnosed as exudates. The diagnostic criteria for malignant pleural effusions were the presence of malignant tumor cells in pleural effusions or biopsy specimens. The diagnostic criteria for peripneumonia effusion were acute fever, purulent sputum, and pulmonary infiltration. Bacteria were found in pleural effusion culture or antibiotic therapy was effective. The diagnosis of tuberculous pleural effusion was based on the positive culture of mycobacterium tuberculosis or the diagnosis of caseous granuloma or pleural fluid thymidine deaminase > 40 u/l with an improvement of the pleurisy after antituberculous treatment.

**Sample collection and determination of TuM2-PK and CEA levels**

Pleural effusion was collected by percutaneous thoracic puncture and blood samples were simultaneously collected by vein for different tests. The extracted blood was coagulated under RT for 15 minutes and centrifuged at 3000 revolutions per minute for 15 minutes to obtain serum. Under the same conditions, the pleural effusion was centrifuged and the cell-free supernatant was collected. Aliquots of serum and pleural fluid from this study were stored at \(-70 ^\circ\text{C}\) until analysis. TuM2-PK (Sche-Bo W Tech, Giessen, Germany) concentrations in serum and pleural fluid were measured by sandwich enzyme-linked immunosorbent assay (ELISA). CEA concentrations were measured by an electrochemiluminescence Kit (Roche Diagnostics, Beijing, China).

**Statistical analysis**

We used commercial SPSS 18.0 software for statistical analysis. Measurement data and numeration data were compared with t test and \( \chi^2 \) test, respectively. Diagnostic accuracy of tumor markers was compared by analyzing receiver operating characteristic (ROC). Results from patients with MPE were...
used to select cut-off values for sensitivity and specificity for all markers. Values of $P < 0.05$ were considered to indicate statistical significance.

**Results**

**Clinical characteristics**

Our study included 205 patients who were diagnosed with MPE and BPE. Among MPE patients, 91 (72.8%) were diagnosed with liquid cytology, 28 (22.4%) with blind pleural biopsy and 6 (4.8%) with thoracoscopic biopsy. The median age of the patients was 68 years (range: 32–78 years), and 80 patients were male (64.0%). Most patients showed adenocarcinoma (64.0%). In patients with BPE, acid fast bacilli were found in Mycobacterium tuberculosis isolated from liquid smears and cultures of 10 patients, and chronic granuloma was found in pleural biopsy of 57 patients with BPE. In addition, a clear diagnosis was made and other possibilities were excluded. The demographic characteristics are shown in Table 1.

| Variables          | MPE group | BPE group | P value |
|--------------------|-----------|-----------|---------|
| Subject, NO        | 125       | 80        |         |
| Age (year)         | 58.5 ± 11.8 | 59.2 ± 10.6 | > 0.05 |
| Male/Female        | 80/45     | 50/30     | > 0.05  |
| **MPE**            |           |           |         |
| Adenocarcinoma     | 80        | ND        |         |
| Squamous cell carcinoma | 25   | ND        |         |
| Small cell lung carcinoma | 20  | ND        |         |
| **BPE**            |           |           |         |
| Tuberculosis       | ND        | 50        |         |
| Parapneumonic      | ND        | 30        |         |

MPE: malignant pleural effusion; BPE: benign pleural effusion; ND: no data.

**Concentration of TuM2-PK and CEA in serum and pleural effusion**

As shown in Table 2, patients with MPE presented higher serum and pleural effusion levels of TuM2-PK and CEA than those with BPE, the differences were statistically significant ($P < 0.05$). The P/S ratio was also significantly higher in MPE group than that in BPE group for TuM2-PK as well as CEA ($P < 0.05$).
Table 2
Concentration of TuM2-PK and CEA in serum and pleural effusion and P/S ratio in BPE and MPE.

| Marker         | MPE (u/ml) | BPE (u/ml) | P value |
|----------------|------------|------------|---------|
| TuM2-PK        | Pleural effusion | 56.38 ± 18.51 | 13.51 ± 1.65 | 0.001 |
|                | Serum      | 33.25 ± 11.71 | 9.67 ± 2.87 | 0.001 |
|                | P/S        | 1.79 ± 1.03  | 1.45 ± 0.46 | 0.034 |
| CEA (ng/ml)    | Pleural effusion | 37.28 ± 14.03 | 4.83 ± 0.48 | 0.001 |
|                | Serum      | 21.57 ± 5.54 | 4.46 ± 0.63 | 0.001 |
|                | P/S        | 1.78 ± 1.16  | 1.07 ± 0.08 | 0.021 |

MPE: malignant pleural effusion; BPE: benign pleural effusion.

Comparison of serum and pleural effusion TuM2-PK and CEA levels depending on etiology of MPE

The levels of TuM2-PK in pleural effusion and serum of SCLC were significantly higher than that of lung ADC and SCC (P < 0.01), while the level of TuM2-PK in pleural effusion and serum of lung ADC was also higher than that of lung SCC (P < 0.05); CEA increased most significantly in lung ADC, and its level was significantly higher in lung SCC and SCLC (P < 0.05)(Fig. 1A-D).

Diagnostic value of TuM2-PK and CEA in MPE patients

ROC curves were plotted to determine the diagnostic efficiency of pleural effusion and serum TuM2-PK and CEA levels for MPE. ROC curve analysis showed that the area under the curve (AUC) of pleural effusion TuM2-PK, pleural effusion CEA and their combination were 0.856 (95% CI: 0.781–0.932), 0.732 (95% CI: 0.631–0.832) and 0.922 (95% CI: 0.867–0.977), respectively. The AUC of serum TuM2-PK, serum CEA, and their combination were 0.816 (95% CI: 0.729–0.903), 0.665 (95% CI: 0.556–0.774) and 0.863 (95% CI: 0.788–0.938), respectively. Therefore, the combination of the index is better than any single index (Table 3 and Fig. 2A-C).
Table 3
Measures of diagnostic accuracy for TuM2-PK and CEA assays in pleural effusion and serum in MPE.

| Marker         | Cut-off          | AUC (95% CI) | Sensitivity (%) | Specificity (%) | Accuracy (%) | PPV (%) | NPV (%) |
|----------------|------------------|--------------|-----------------|-----------------|--------------|---------|---------|
| TuM2-PK        | Pleural effusion | 28.67 u/ml   | 0.856 (0.781–0.932) | 68.8            | 52.5         | 62.4    | 69.4    | 51.9    |
|                | Serum            | 15.83 u/ml   | 0.816 (0.729–0.903) | 60.8            | 58.8         | 60.0    | 69.7    | 49.0    |
| CEA            | Pleural effusion | 8.76 ng/ml   | 0.732 (0.631–0.832) | 61.6            | 71.3         | 65.4    | 77.0    | 54.3    |
|                | Serum            | 5.53 ng/ml   | 0.665 (0.556–0.774) | 51.2            | 63.8         | 56.1    | 68.8    | 45.5    |
| TuM2-PK + CEA  | Pleural effusion |              | 0.922 (0.867–0.977) | 91.2            | 83.8         | 88.3    | 89.8    | 85.9    |
|                | Serum            |              | 0.863 (0.788–0.938) | 80.8            | 71.3         | 77.1    | 81.5    | 70.4    |

AUC: area under the curve; PPV: positive predictive value; NPV: negative predictive value.

Table 3 shows the diagnostic sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of TuM2-PK and CEA for diagnosing MPE. Cutoff points were determined by the maximum sum of sensitivity and specificity. The cutoff values of TuM2-PK and CEA in pleural effusion were 28.67 u/l and 8.76 ng/ml, the sensitivity was 68.8% and 61.6%, the specificity was 52.5% and 71.3%, respectively. With a cut-off value of 15.83 u/l and 5.53 ng/ml in serum TuM2-PK and CEA, the sensitivity was 60.8% and 51.2%, the specificity was 58.8% and 63.8%, respectively.

As shown in Table 3, the diagnostic efficiency of each marker was slightly higher in pleural effusion than in serum. The diagnostic efficiency of TuM2-PK alone was higher than CEA alone. The combined detection of TuM2-PK and CEA in pleural effusion or serum was superior to that of any single detection.

**Correlation between TuM2-PK and CEA in MPE patients**
There is a significant correlation between TuM2-PK and CEA levels in serum (Fig. 3A) and pleural effusion (Fig. 3B), respectively \( (r = 0.647, P = 0.001; r = 0.531, P = 0.003) \).

**Discussion**

The etiological diagnosis of pleural effusion is a clinical problem, and the traditional methods have been proved to be insufficient [15, 16]. Traditional pleural fluid cytology has been used to detect tumor cells in pleural fluid. However, sensitivity varies from 30–60% and the additional sensitivity provided by blindly obtained pleural needle biopsy specimens is minimal [17]. Although thoracoscopy is more sensitive to malignant cases, they are expensive and not available in all medical centres [18]. In recent years, with the development of tumor molecular biology, tumor markers have been widely used in the diagnosis of pleural effusion. We investigated TuM2-PK in the serum and pleural effusion of patients with pleural effusion caused by benign disease or lung cancer.

PK has four isozymes: L-type, R-type, M1 type and M2 type. M2 type is mainly expressed in lung, distal convoluted tubules of normal kidney, embryo and or proliferative tissues. There are many reasons for the abnormal expression of TuM2-PK in malignant tumors. It has been confirmed that, on the one hand, due to the phosphorylation of M2-PK tyrosine site, the tetramer is dissociated into dimer, and M2-PK is preferentially expressed in tumor cells in the form of dimer with low affinity for phosphorylated pyruvate. TuM2-PK has very low affinity for phosphoenolpyruvate, resulting in the accumulation of phosphoenols and significantly reducing the degradation of fructose 1, 6-diphosphate to pyruvate, And DNA synthesis increased. In addition, abnormal energy metabolism in malignant tumors is also one of the main reasons for the increase of TuM2-PK. Previous studies have shown that TuM2-PK can be detected in body fluids, which may be due to the release of TuM2-PK during tumor necrosis or metastasis [19]. It has been reported that TuM2-PK was significantly increased in MPE, which can be used as an index to distinguish BPE and MPE [20]. The results showed that the levels of TuM2-PK in pleural effusion and serum of patients with MPE were significantly higher than those of patients with BPE, and increased most significantly in SCLC, which was significantly higher than those of lung ADC and SCC, while the levels of TuM2-PK in pleural effusion and serum of patients with ADC were also higher than those of patients with SCC, Therefore, TuM2-PK plays a certain role in the typing and diagnosis of lung cancer. We found that the expression level of TuM2-PK in pleural effusion of patients with MPE was significantly higher than that in serum. Therefore, it is considered that TuM2-PK plays an important role in the accumulation of pleural effusion. Detection of TuM2-PK level is important for differential diagnosis of BPE and MPE.

CEA is a glycoprotein, which mainly exists in the intestine, liver and pancreas of the fetus before 6 months of pregnancy. Due to the large molecular weight of CEA, it synthesized and released by pleural metastasis to pleural effusion is not easy to enter human blood circulation, so it rises earlier in pleural effusion and its level is also significantly higher than that in serum. CEA has been widely used in the diagnosis of a variety of tumors. The concentration of CEA increases in the serum of 30% ~ 80% of lung cancer patients. The degree of increase is directly related to the number of cancer cells, and the positive rate for the diagnosis of lung ADC is the highest [21]. The results also confirmed that the CEA
concentration and positive rate of lung ADC were significantly higher than those of SCC and SCLC, which was consistent with the literature report. There are also many reports on the use of CEA in the differential diagnosis of pleural effusion [22, 23]. The results of this study demonstrated that the CEA levels of serum and pleural effusion in MPE were significantly higher than those in BPE, which was basically consistent with the report [10–14].

We detected TuM2-PK and CEA in serum and pleural effusion of patients with MPE alone and in combination. It was found that the sensitivity and specificity of a single detection index in the diagnosis of MPE were less than 80%. Combined detection could increase the sensitivity and specificity. Therefore, the combined detection of TuM2-PK and CEA in serum and pleural effusion is helpful to the differential diagnosis of MPE and BPE, and combined detection is helpful to the pathological classification and clinical diagnosis of pleural effusion.

Our findings demonstrate that determining serum and pleural effusion levels of the markers TuM2-PK and CEA is useful in differentiating between MPE and BPE. In comparison with either single determination of concentration in serum or pleural effusion, the combined detection of two markers was important in the diagnosis of lung cancer. In clinical practice, when the cytopathological examination of pleural effusion is negative, the simultaneous detection of TuM2-PK and CEA levels in serum and pleural effusion may help clinicians decide whether to obtain cytological or histological specimens by invasive methods to investigate the possible diagnosis of malignant tumors.

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Nanjing Brain Hospital and was carried out in accordance with national law and the current revised Declaration of Helsinki. Informed consent was obtained from all participants in the study.

Consent for publication

Not applicable.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Competing interests

The authors declare no any conflicts of interest in this work.

Funding
The study was supported by the Major Program of Nanjing Medical Science and Technique Development Foundation (ZKX17044).

Authors' contributions

TTZ, WL and CHX carried out most of the experiment and writing this manuscript; LL and JZ collected data; WL and TTZ helped the design and all through the research. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

References

1. Wang XF, Wu YH, Wang MS, Wang YS. CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause. Asian Pac J Cancer Prev. 2014; 15(1): 363–8.

2. Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology. 2015; 20(4): 654–9.

3. Xu C, Qian L, Yu L, Zhang X, Wang Q. Evaluation of serum and pleural levels of soluble B7-H4 in lung cancer patients with pleural effusion. Biomarkers. 2015; 20(4): 271–4.

4. Xu C, Yu L, Zhan P, Zhang Y. Elevated pleural effusion IL-17 is a diagnostic marker and outcome predictor in lung cancer patients. Eur J Med Res. 2014; 19(1): 23.

5. Trapé J, Molina R, Sant F, Montesinos J, Arnau A, Franquesa J, Blavia R, Martín E, Marquilles E, Perich D, Pérez C, Roca JM, Doménech M, López J, Badal JM. Diagnostic accuracy of tumour markers in serous effusions: a validation study. Tumour Biol. 2012; 33(5): 1661–8.

6. Hooper CE, Welham SA, Maskell NA; British Thoracic Society. Pleural procedures and patient safety: a national BTS audit of practice. Thorax. 2015; 70(2): 189–91.

7. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005; 15(4): 300–8.

8. Ventrucci M, Cipolla A, Racchini C, Casadei R, Simoni P, Gullo L. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci. 2004; 49(7–8): 1149–55.

9. Zhang B, Chen J, Chen D, Wang G, Shen P. Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls. World J Gastroenterol 2004; 10(11): 1643–6.

10. Shi HZ, Liang QL, Jiang J, Qin XJ, Yang HB. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology. 2008; 13(4): 518–27.

11. Hackner K, Errhalt P, Handzhiev S. Ratio of carcinoembryonic antigen in pleural fluid and serum for the diagnosis of malignant pleural effusion. Ther Adv Med Oncol. 2019; 11:1758835919850341.

12. Zhang F, Hu L, Wang J, Chen J, Chen J, Wang Y. Clinical value of jointly detection serum lactate dehydrogenase/pleural fluid adenosine deaminase and pleural fluid carcinoembryonic antigen in the
identification of malignant pleural effusion. J Clin Lab Anal. 2017; 31(5): e22106.

13. Li R, Gao Z, Dong K, Wang H, Zhang H. Detection of carcinoembryonic antigen levels in pleural effusion and serum and their ratio for differential diagnosis of pleural effusion resulting from tuberculosis and lung cancer. Nan Fang Yi Ke Da Xue Xue Bao. 2019; 39(2): 175–80.

14. Li H, Huang L, Tang H, Zhong N, He J. Pleural fluid carcinoembryonic antigen as a biomarker for the discrimination of tumor-related pleural effusion. Clin Respir J. 2017; 11(6): 881–6.

15. Aoe K, Hiraki A, Murakami T, Murakami K, Makihata K, Takao K, Eda R, Maeda T, Sugi K, Darzynkiewicz Z, Takeyama H. Relative abundance and patterns of correlation among six cytokines in pleural fluid measured by cytometric bead array. Int J Mol Med. 2003; 12(2): 193–8.

16. Hiraki A, Aoe K, Eda R, Maeda T, Murakami T, Sugi K, Takeyama H. Comparison of six biological markers for the diagnosis of tuberculous pleuritis. Chest. 2004; 125(3): 987–9.

17. Heffner JE. Diagnosis and management of malignant pleural effusions. Respirology. 2008; 13(1): 5–20.

18. Wu YB, Xu LL, Wang XJ, Wang Z, Zhang J, Tong ZH, Shi HZ. Diagnostic value of medical thoracoscopy in malignant pleural effusion. BMC Pulm Med. 2017; 17(1): 109.

19. Mazurnk S, Boeshnk CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005, 15 (4): 300–308.

20. Elia S, Massoud R, Guggino G, Cristino B, Cortese C, De Massimi AR, Zenobi R. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures. Eur J Cardiothorac Surg. 2008; 33(4): 723–7.

21. Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012; 76(2): 138–43.

22. Wei F, Wei Y, Li LF, Li GL, Wang GJ. The value of B7-H4 and carcinoembryonic antigen in diagnosing the benign and malignant pleural effusion. China J Oncol. 2017; 39(7): 524–7.

23. Dong J, Sun G, Zhu H. Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in differentiating malignant from benign pleural effusion. Tumour Biol. 2016; 37(3): 3257–64.

Figures
Figure 1

Comparison of serum and pleural effusion TuM2-PK (A, B) and CEA (C, D) levels depending on etiology of MPE.

Figure 2
**ROC curve in pleural effusion.** TuM2-PK ROC curve (A), CEA ROC curve (B), TuM2-PK+CEA ROC curve (C). The AUC of pleural effusion TuM2-PK, CEA and TuM2-PK+CEA were 0.856, 0.732, and 0.922, respectively.

**Figure 3**

**Correlation between TuM2-PK and CEA in MPE patients.** There is a significant correlation between TuM2-PK and CEA levels in serum (A) and pleural effusion (B), respectively. ($r=0.647$, $P=0.001$; $r=0.531$, $P=0.003$).